Abstract

Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 …

Legal parties

Party
Inventors (applicants): Pravin Kaumaya
Assignees (initial): The Ohio State University Research Foundation (Columbus, US)
Agents: Ballard Spahr LLP (attorney)

The application was examined by Laura B Goddard (USPTO dept. 1642)

Claims

  • 1. An immunogenic composition comprising a chimeric peptide, wherein the chimeric peptide comprises a HER-2 …
  • 2. The composition according to claim 1 wherein at least one of the HER-2 B epitope …
  • 3. The composition according to claim 1 wherein the linker comprises 2 to 15 amino …

Cited documents

Patents

  • Cheever et al. US 5876712 A / 424/93.7, Mar. 1, 1999
  • Cheever et al. US 5801005 A / 435/7.024, Sep. 1, 1998
  • WO WO 94/07531, Apr. 1, 1994
  • Kaumaya et al. US 2012/0201841 A1, Aug. 1, 2012
  • Paton et al. US 7892549 B2 / 424/143.1, Feb. 1, 2011
  • WO WO 2004/113380, Dec. 1, 2004
  • Cheever et al. US 5773230 A / 435/7.23, Jun. 1, 1998
  • NZ 564951, Jun. 1, 2005
  • Takeshita et al. US 2006/0188976 A1 / 435/183, Aug. 1, 2006
  • EP 06785065.1, Jun. 1, 2005
  • NZ 564951, Jun. 1, 2006
  • WO WO 94/07530, Apr. 1, 1994
  • JP 2012-93680, Jun. 1, 2005
  • JP 2004522412, Jul. 1, 2004
  • EP 12170985.1, Jun. 1, 2012
  • Cheever et al. US 5726023 A / 435/7.1, Mar. 1, 1998
  • WO WO 00/34337, Jun. 1, 2000
  • WO WO 97/38011, Oct. 1, 1997
  • WO WO 98/17797, Apr. 1, 1998
  • WO PCT/US2006/023672, Jun. 1, 2005
  • Hudziak et al. US 6165464 A / 424/131.1, Dec. 1, 2000
  • CA 2555274, Feb. 1, 2005
  • WO WO 95/17210, Jun. 1, 1995
  • Cheever et al. US 6075122 A / 530/350, Jun. 1, 2000
  • EP 00953823.2, Aug. 1, 2000
  • WO PCT/US2005/003747, Feb. 1, 2005
  • Kaumaya et al. US 2010/0234283 A1, Sep. 1, 2010
  • Cohen et al. US 2003/0170235 A1 / 424/193.1, Sep. 1, 2003
  • JP 2012-93680, Apr. 1, 2012
  • Kaumaya US 8110657 B2, Feb. 1, 2012
  • WO WO 02/14503, Feb. 1, 2002
  • Vandlen et al. US 5840525 A / 435/69.1, Nov. 1, 1998
  • WO WO 01/08636, Feb. 1, 2001
  • WO WO 2006/138675, Jun. 1, 2006
  • CA 2612394, Jun. 1, 2005
  • WO WO 2005/076972, Aug. 1, 2005
  • JP 2008-517193, Jun. 1, 2005
  • Cheever et al. US 5846538 A / 424/185.1, Dec. 1, 1998
  • JP 2003520781, Jul. 1, 2003
  • Kaumaya et al. US 8080253 B2 / 424/192.1, Dec. 1, 2011
  • Kaumaya et al. US 7666430 B2 / 424/185.1, Feb. 1, 2010
  • AU 2005213457, Feb. 1, 2005
  • WO WO 96/34888, Nov. 1, 1996
  • WO WO 96/02555, Feb. 1, 1996
  • Kaumaya et al. US 2012/0121626 A1, May. 1, 2012
  • EP 06785065.1, Jun. 1, 2006
  • Gu et al. US 6339139 B1 / 530/300, Jan. 1, 2002
  • WO WO 2005/039616, May. 1, 2005
  • CA 2612394, Jun. 1, 2006
  • Glover et al. US 2006/0110400 A1 / 424/185.1, May. 1, 2006
  • Hudziak et al. US 6015567 A / 424/277.1, Jan. 1, 2000
  • EP 05722777.9, Feb. 1, 2005
  • Humphreys et al. US 2003/0235594 A1 / 424/192.1, Dec. 1, 2003
  • WO PCT/US2000/021222, Aug. 1, 2003
  • WO WO 01/21193, Mar. 1, 2001
  • Kaumaya et al. US 7691396 B2 / 424/277.1, Apr. 1, 2010
  • WO WO 2004/030616, Apr. 1, 2004
  • AU 2006261342, Jun. 1, 2006
  • WO WO 2006/138675, Dec. 1, 2006
  • WO WO 2004/078907, Sep. 1, 2004
  • JP 2008-517193, Jun. 1, 2006
  • AU 2006261342, Jun. 1, 2005
  • Kaumaya et al. US 7060284 B1 / 424/277.1, Jun. 1, 2006
  • WO WO 94/00153, Jan. 1, 1994
  • JP 2001-513369, Aug. 1, 2000
  • Cheever et al. US 5869445 A / 514/2, Feb. 1, 1999
  • WO WO 99/31140, Jun. 1, 1999
  • WO WO 96/33739, Oct. 1, 1996
  • Cheever et al. US 5601989 A / 435/7.23, Feb. 1, 1997

Brief Description of the Several Views of the Drawings

The following detailed description of embodiments of the present invention can be best understood when read in conjunction with the following drawings, where like structure is indicated with like reference …

Description

Background

Currently, the most common approaches to treating breast cancer involve surgery, chemical intervention, and/or radiotherapy. Unless the cancer is restricted to a defined area, surgery alone cannot eliminate the cancer. …

Cross-Reference to Related Applications

This application is a continuation of application Ser. No. 11/424,526, filed Jun. 15, 2006, now U.S. Pat. No. 7,691,396, which claims the benefit of U.S. Provisional Application No. 60/690,574, filed …

Detailed Description of Embodiments of the Invention

The present invention will now be described with occasional reference to the specific embodiments of the invention. This invention may, however, be embodied in different forms and should not be construed …

More details about Chimeric Peptides Comprising HER-2 B-Cell Epitopes and T-Helper Epitopes

Miscellaneous patent data

The patent was granted on Jun. 25, 2013, the claim number 1 is selected as exemplary, the inventor's first name is Pravin, and his last name is Kaumaya, the inventor's address - Westerville, OH, the patent is illustrated by 22 drawings, the assignee is categorized as a United States company, the recorded agent - Ballard Spahr LLP, 33 figures depict the invention details, the invention is titled Chimeric Peptides Comprising HER-2 B-Cell Epitopes and T-Helper Epitopes, numbered 12/697,578 (application), developed by Pravin Kaumaya, the application was published on Feb. 1, 2010, the drawings include the following: synthetic strategy for 3 disulfide, trastuzumab specifically recognizes peptide epitopes, immune response in FVB/n mice., Chimeric Peptides Comprising HER-2 B-Cell, 20 claims comprise the protection scope, was examined by Laura B Goddard, the main examiner (1642 USPTO department), particularly claims an immunogenic composition comprising a chimeric peptide, wherein the chimeric…, located in Columbus (US), the assignee company is The Ohio State University Research Foundation, the grant number is 08470333 (publication number), the published applicant's name is Kaumaya Pravin, the applicant's state - OH, city - Westerville, similar classification categories are having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid, Clostridium, having seven-membered rings, e.g. azelastine, pentylenetetrazole, containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin, Reoviridae, Binds parasitic organism, or multicellular endoparasite) or component thereof or substance produced by said parasitic organism, Containing emulsions, dispersions, or solutions, Calcitonins, Bandages with incorporated medicaments, Depsipeptides, Derivatives thereof, the primary classification Fusion protein or fusion polypeptide has been designated to the document.

Invention classification information

The invention is classified under Conjugated via claimed linking group, bond, or coupling agent, Amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same, Peptides of 3 to 100 Amino Acid Residues, Fusion protein or fusion polypeptide, Medicinal preparations containing antigens or antibodies.

Patent details
Publication number 08470333
Publication date Jun. 25, 2013
Kind code B2
Application number 12/697,578
Application date Feb. 1, 2010
Application type U
Application series code 12
National classification 424/192.1
Total number of claims 20
Exemplary claims 1
Number of drawings 22
Number of figures 33
Terminal disclaimer
Quick navigation
More similar inventions

Photochrome- or Near IR Dye-Coupled Polymeric Matrices for Medical Articles (US08722076, May 13, 2014 / 13/248,203, Sept. 29, 2011, Surgical implant or material), Emily R. Rolfes Meyering et al. / SurModics, Inc. (Eden Prairie, US)

Murgantiol as a Stink Bug Synergistic Attractant for Use Outdoors (US08663620, March 4, 2014 / 13/410,124, March 1, 2012, Baits, Attractants, or Lures (Non-Food)), Qing-He Zhang et al. / Sterling International Inc. (Spokane, US)

Aqueous Antiperspirant Composition (US08557228, Oct. 15, 2013 / 13/518,957, Dec. 16, 2010, Anti-Perspirants or Perspiration Deodorants), Michael C. Fitzgerald et al. / Colgate-Palmolive Company (New York, US)

Also viewed with this patent

Multi-Drug Ligand Conjugates (US08465724, June 18, 2013 / 12/064,191, Aug. 18, 2006, Attachment via an added element), Christopher Paul Leamon et al. / Endocyte, Inc. (West Lafayette, US)

Use of Silymarin and Silybin in the Treatment of Neural Injury (US08481094, July 9, 2013 / 12/754,305, April 5, 2010, Containing or obtained from a seed or nut), May-Jywan Tsai et al. / Taipei Veterans General Hospital (Taipei, TW)

Targeted Therapeutics Based on Engineered Proteins for Tyrosine Kinases Receptors, Including IGF-IR (US08470332, June 25, 2013 / 12/312,725, Nov. 21, 2007, Amino acid sequence disclosed in whole or in part; or conjugate, complex, or fusion protein or fusion polypeptide including the same), Ray Camphausen et al. / Bristol-Myers Squibb Company (Princeton, US)

New documents
  • Process for the Production of the Actinobacillus Pleuropneumoniae Toxins APXI or APXIII in a Liquid Culture Medium Under Supply of Air Enriched in Carbon Dioxide
  • Method for Manufacturing Nonvolatile Memory Device
  • Supply Chain Demand Satisfaction
  • Supply-Line Management Device
  • Storage Control Device and Method for Managing Snapshot